Page last updated: 2024-11-04

vorinostat and Angiosarcoma

vorinostat has been researched along with Angiosarcoma in 1 studies

Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Suzuki, T1
Aoshima, K1
Yamazaki, J1
Kobayashi, A1
Kimura, T1

Other Studies

1 other study available for vorinostat and Angiosarcoma

ArticleYear
Manipulating histone acetylation leads to antitumor effects in hemangiosarcoma cells.
    Veterinary and comparative oncology, 2022, Volume: 20, Issue:4

    Topics: Acetylation; Animals; Apoptosis; Cell Line, Tumor; Dog Diseases; Dogs; Endothelial Cells; Hemangiosa

2022